Das Srijit, Sakthiswary Rajalingham
Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, 56000, Kuala Lumpur, Malaysia.
Curr Drug Targets. 2013 Dec;14(14):1667-74. doi: 10.2174/1389450114666131217001756.
Preventing osteoporotic fractures in millions of individuals may significantly reduce the associated morbidity and health-care expenditures incurred. As such, the search for newer anti-osteoporotic agents has been ongoing for years. Genetic studies have proven that the secreted protein sclerostin is one of the main culprits, which negatively regulates the bone formation. Recently, sclerostin-neutralizing monoclonal antibodies (Scl-Ab) in rodent studies have shown positive effects on bone homeostasis. An extensive search of the literature was performed in the BIOSIS, Cinahl, EMBASE, Pub- Med, Web of Science and Cochrane Library databases to evaluate the published murine studies on the effects of Scl-Ab on the bone metabolism and histomorphometric parameters. Our systematic review depicts a significant association between Scl-Ab administration and improvement in bone formation, bone density, bone volume and trabecular thickness.
预防数百万个体的骨质疏松性骨折可能会显著降低相关的发病率和医疗保健支出。因此，多年来一直在寻找更新的抗骨质疏松药物。基因研究已证明，分泌蛋白硬化素是主要罪魁祸首之一，它对骨形成起负调节作用。最近，在啮齿动物研究中，硬化素中和单克隆抗体（Scl-Ab）已显示出对骨稳态有积极作用。我们在BIOSIS、护理学与健康领域数据库（Cinahl）、荷兰医学文摘数据库（EMBASE）、医学期刊数据库（PubMed）、科学引文索引数据库（Web of Science）和考科蓝图书馆数据库中广泛检索文献，以评估已发表的关于Scl-Ab对骨代谢和组织形态计量学参数影响的小鼠研究。我们的系统评价表明，给予Scl-Ab与骨形成、骨密度、骨体积和小梁厚度的改善之间存在显著关联。
